Home LiteratureArticle Details
PMID: 19498435 Published · ppublish English Journal Article Review

Brain-derived neurotrophic factor in neurodegenerative diseases.

Nature reviews. Neurology ·Vol. 5 ·No. 6 ·2009-06-00 ·Pages 311-22

Zuccato C, Cattaneo E

Abstract

Changes in the levels and activities of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), have been described in a number of neurodegenerative disorders, including Huntington disease, Alzheimer disease and Parkinson disease. It is only in Huntington disease, however, that gain-of-function and loss-of-function experiments have linked BDNF mechanistically with the underlying genetic defect. Altogether, these studies have led to the development of experimental strategies aimed at increasing BDNF levels in the brains of animals that have been genetically altered to mimic the aforementioned human diseases, with a view to ultimately influencing the clinical treatment of these conditions. In this article, we will review the current knowledge about the involvement of BDNF in a number of neurodegenerative diseases, with particular emphasis on Huntington disease, and will provide the rationale for and discuss the problems in proposing BDNF treatment as a beneficial and feasible therapeutic approach in the clinic.

MeSH Terms
Animals Brain-Derived Neurotrophic Factor/genetics,metabolism,therapeutic use Humans Models, Biological Neurodegenerative Diseases/classification,genetics,metabolism,therapy PubMed/statistics & numerical data
Chemicals
Brain-Derived Neurotrophic Factor
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Zuccato Chiara
Department of Pharmacological Sciences and Center for Stem Cell Research, University of Milan, via Balzaretti 9, Milan, Italy.
Cattaneo Elena
References (118)
118 references, click to expand
  1. Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued.
    J Biol Chem. 2008 Dec 12;283(50):34880-6 PMID: 18922795
  2. Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease.
    Genes Brain Behav. 2009 Feb;8(1):43-52 PMID: 18786162
  3. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease.
    Neuroscience. 1999;88(4):1015-32 PMID: 10336117
  4. Brain-derived neurotrophic factor genetic variants are not susceptibility factors to Alzheimer's disease in Italy.
    Ann Neurol. 2004 Mar;55(3):447-8 PMID: 14991827
  5. Brain-derived neurotrophic factor in Huntington disease.
    Brain Res. 2000 Jun 2;866(1-2):257-61 PMID: 10825501
  6. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset.
    Neurosci Lett. 2003 Dec 15;353(1):75-7 PMID: 14642442
  7. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior.
    Physiol Rev. 2002 Jul;82(3):637-72 PMID: 12087131
  8. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease.
    Mol Psychiatry. 2001 Jan;6(1):83-6 PMID: 11244490
  9. No evidence of association between BDNF gene variants and age-at-onset of Huntington's disease.
    Neurobiol Dis. 2006 Nov;24(2):274-9 PMID: 16905325
  10. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta.
    J Neurosci. 2005 Jun 29;25(26):6251-9 PMID: 15987955
  11. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
    J Clin Invest. 2008 Sep;118(9):3132-42 PMID: 18688285
  12. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease.
    J Neurochem. 2005 Jun;93(6):1412-21 PMID: 15935057
  13. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons.
    Hum Mol Genet. 2008 Dec 15;17(24):3837-46 PMID: 18772195
  14. Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer's disease and age of onset.
    Neuropsychobiology. 2004;49(1):10-2 PMID: 14730194
  15. Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine.
    J Neurosci Res. 2002 Nov 1;70(3):519-27 PMID: 12391613
  16. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
    Nature. 1997 Mar 27;386(6623):395-9 PMID: 9121555
  17. Studies on the physiological role of brain-derived neurotrophic factor and neurotrophin-3 in knockout mice.
    Int J Dev Biol. 1995 Oct;39(5):799-807 PMID: 8645564
  18. Differential loss of striatal projection neurons in Huntington disease.
    Proc Natl Acad Sci U S A. 1988 Aug;85(15):5733-7 PMID: 2456581
  19. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.
    J Neurosci. 2004 Sep 1;24(35):7727-39 PMID: 15342740
  20. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease.
    Prog Neurobiol. 2001 Jan;63(1):71-124 PMID: 11040419
  21. Brain-derived neurotrophic factor gene polymorphisms and Alzheimer's disease.
    J Neural Transm (Vienna). 2005 May;112(5):703-11 PMID: 15375678
  22. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.
    Cell. 1998 Oct 2;95(1):55-66 PMID: 9778247
  23. No association between the brain-derived neurotrophic factor 196 G>A or 270 C>T polymorphisms and Alzheimer's or Parkinson's disease.
    Folia Neuropathol. 2006;44(1):12-6 PMID: 16565926
  24. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease.
    Nat Med. 2009 Mar;15(3):331-7 PMID: 19198615
  25. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.
    Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18171-6 PMID: 15604149
  26. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.
    Nat Med. 2005 May;11(5):551-5 PMID: 15852017
  27. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
    Nat Med. 2003 May;9(5):589-95 PMID: 12669033
  28. The expanding role of BDNF: a therapeutic target for Alzheimer's disease?
    Pharmacogenomics J. 2006 Jan-Feb;6(1):8-15 PMID: 16314887
  29. Trk receptor alterations in Alzheimer's disease.
    Brain Res Mol Brain Res. 1996 Nov;42(1):1-17 PMID: 8915574
  30. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression.
    Brain Res Mol Brain Res. 1996 Sep 5;41(1-2):14-26 PMID: 8883930
  31. The brain-derived neurotrophic factor Val66Met polymorphism and rate of decline in Alzheimer's disease.
    J Alzheimers Dis. 2006 Mar;9(1):43-9 PMID: 16627933
  32. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Mol Cell Neurosci. 2008 Sep;39(1):1-7 PMID: 18571429
  33. Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)- blood levels in Alzheimer's disease.
    Thromb Haemost. 2006 Jul;96(1):102-3 PMID: 16807663
  34. Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats.
    Neurobiol Dis. 2008 Sep;31(3):316-26 PMID: 18585459
  35. Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease.
    Am J Med Genet B Neuropsychiatr Genet. 2005 Apr 5;134B(1):1-5 PMID: 15635706
  36. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease.
    J Neurosci. 2007 Jun 27;27(26):6972-83 PMID: 17596446
  37. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms.
    Exp Neurol. 2005 Jul;194(1):91-6 PMID: 15899246
  38. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
    J Neurochem. 2008 Apr;105(2):369-79 PMID: 18086127
  39. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin.
    J Neurosci. 2008 Dec 10;28(50):13662-72 PMID: 19074039
  40. Analysis of the repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy of non-neuronal genes in peripheral lymphocytes from patients with Huntington's disease.
    Brain Pathol. 2010 Jan;20(1):96-105 PMID: 19134002
  41. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.
    Science. 2001 Jul 20;293(5529):493-8 PMID: 11408619
  42. Assessment of Alzheimer's disease case-control associations using family-based methods.
    Neurogenetics. 2009 Feb;10(1):19-25 PMID: 18830724
  43. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease.
    Neurology. 2005 Sep 27;65(6):964-5 PMID: 16186551
  44. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease.
    Neuroreport. 1996 Nov 25;7(18):2925-8 PMID: 9116211
  45. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice.
    J Neurosci. 2004 Mar 10;24(10):2421-30 PMID: 15014117
  46. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III).
    Neurology. 1999 Apr 22;52(7):1427-33 PMID: 10227630
  47. Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism.
    Neurosci Lett. 2005 Jun 24;381(3):275-8 PMID: 15896483
  48. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.
    Nature. 1986 May 8-14;321(6066):168-71 PMID: 2422561
  49. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition.
    Neurology. 2005 Sep 13;65(5):745-7 PMID: 16157910
  50. Toward identification of susceptibility genes for sporadic Parkinson's disease.
    J Neurol. 2003 Oct;250 Suppl 3:III40-3 PMID: 14579123
  51. Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease.
    Hum Genet. 2006 Sep;120(2):285-92 PMID: 16847693
  52. Molecular Trojan horses for blood-brain barrier drug delivery.
    Discov Med. 2006 Aug;6(34):139-43 PMID: 17234133
  53. BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson's disease in diverse ethnic groups.
    Neurosci Lett. 2007 Mar 19;415(1):59-63 PMID: 17229524
  54. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Exp Neurol. 2005 Mar;192(1):226-34 PMID: 15698637
  55. Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms.
    Curr Alzheimer Res. 2007 Dec;4(5):503-6 PMID: 18220511
  56. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.
    Cell. 1997 Aug 8;90(3):537-48 PMID: 9267033
  57. Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy.
    Mov Disord. 2005 Aug;20(8):1031-3 PMID: 15838855
  58. A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the Apolipoprotein E epsilon4 allele.
    Mol Psychiatry. 2002;7(7):782-5 PMID: 12192623
  59. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
    J Clin Invest. 2006 May;116(5):1410-24 PMID: 16604191
  60. Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease.
    Neurobiol Dis. 2006 Nov;24(2):280-5 PMID: 16962786
  61. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres.
    Nat Med. 1995 Nov;1(11):1189-94 PMID: 7584993
  62. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules.
    Cell. 2004 Jul 9;118(1):127-38 PMID: 15242649
  63. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
    J Neurosci. 2007 Oct 24;27(43):11758-68 PMID: 17959817
  64. Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese Parkinson's disease.
    Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):458-62 PMID: 17427185
  65. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
    Neurobiol Dis. 2005 Dec;20(3):785-98 PMID: 16006135
  66. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease.
    J Med Genet. 2007 Feb;44(2):e66 PMID: 17293537
  67. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles.
    Neuron. 1999 Nov;24(3):521-9 PMID: 10595506
  68. New insights into brain BDNF function in normal aging and Alzheimer disease.
    Brain Res Rev. 2008 Nov;59(1):201-20 PMID: 18708092
  69. Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators.
    J Biol Chem. 2007 Aug 24;282(34):24554-62 PMID: 17565993
  70. BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice.
    Mol Psychiatry. 2003 Nov;8(11):898-9 PMID: 14593425
  71. Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population.
    Ann Neurol. 2003 Jun;53(6):823 PMID: 12783434
  72. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.
    Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Jun;1(3):201-6 PMID: 11464953
  73. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
    Neurosurgery. 1995 Oct;37(4):733-9; discussion 739-41 PMID: 8559303
  74. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.
    FEBS J. 2005 May;272(10):2347-61 PMID: 15885086
  75. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients.
    Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):574-7 PMID: 17427191
  76. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Eur J Neurosci. 2006 Feb;23(3):649-58 PMID: 16487146
  77. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex.
    Neuroscience. 1999;93(4):1491-506 PMID: 10501474
  78. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters.
    Genomics. 2007 Sep;90(3):397-406 PMID: 17629449
  79. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression.
    Neuron. 2006 Feb 2;49(3):341-8 PMID: 16446138
  80. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein.
    J Alzheimers Dis. 2001 Feb;3(1):75-80 PMID: 12214075
  81. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration.
    Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3225-30 PMID: 19218428
  82. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.
    Neurobiol Dis. 2008 Jun;30(3):312-322 PMID: 18403212
  83. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls.
    J Psychiatr Res. 2007 Aug;41(5):387-94 PMID: 16554070
  84. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system.
    Genes Dev. 2000 Dec 1;14(23):2919-37 PMID: 11114882
  85. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease.
    J Clin Invest. 2007 Oct;117(10):2889-902 PMID: 17885687
  86. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons.
    EMBO J. 2008 Aug 6;27(15):2124-34 PMID: 18615096
  87. BDNF and epilepsy: too much of a good thing?
    Trends Neurosci. 2001 Jan;24(1):47-53 PMID: 11163887
  88. SNPs in neurotrophin system genes and Alzheimer's disease in an Italian population.
    J Alzheimers Dis. 2008 Sep;15(1):61-70 PMID: 18780967
  89. No association between polymorphisms in the BDNF gene and age at onset in Huntington disease.
    BMC Med Genet. 2006 Nov 10;7:79 PMID: 17096834
  90. Effective gene therapy with nonintegrating lentiviral vectors.
    Nat Med. 2006 Mar;12(3):348-53 PMID: 16491086
  91. AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment.
    Gene Ther. 2008 Jul;15(13):966-77 PMID: 18323792
  92. Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer's disease (AD) and quantitative measures of AD progression.
    Neurosci Lett. 2005 May 13;379(3):229-34 PMID: 15843069
  93. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line.
    Biochem Biophys Res Commun. 2004 May 21;318(1):113-8 PMID: 15110760
  94. Gene therapy of storage disorders by retroviral and lentiviral vectors.
    Hum Gene Ther. 2005 Oct;16(10):1133-42 PMID: 16218774
  95. Emerging restorative treatments for Parkinson's disease.
    Prog Neurobiol. 2008 Aug;85(4):407-32 PMID: 18586376
  96. Anterograde transport of brain-derived neurotrophic factor and its role in the brain.
    Nature. 1997 Oct 23;389(6653):856-60 PMID: 9349818
  97. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.
    Pharmacogenomics J. 2006 Mar-Apr;6(2):95-104 PMID: 16402079
  98. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.
    Cell. 1993 Mar 26;72(6):971-83 PMID: 8458085
  99. Opinion: neural stem cell therapy for neurological diseases: dreams and reality.
    Nat Rev Neurosci. 2002 May;3(5):401-9 PMID: 11988779
  100. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease.
    Am J Med Genet B Neuropsychiatr Genet. 2005 Apr 5;134B(1):93-103 PMID: 15666411
  101. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes.
    Nat Genet. 2003 Sep;35(1):76-83 PMID: 12881722
  102. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease.
    J Neurochem. 2006 Apr;97(2):475-87 PMID: 16539663
  103. Genetic analysis of BDNF and TrkB gene polymorphisms in Alzheimer's disease.
    J Neurol. 2005 Apr;252(4):423-8 PMID: 15726264
  104. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor.
    J Neurosci. 2004 Apr 28;24(17):4250-8 PMID: 15115821
  105. Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan.
    Dement Geriatr Cogn Disord. 2006;22(3):216-22 PMID: 16899999
  106. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.
    Neurology. 2005 Dec 13;65(11):1823-5 PMID: 16344533
  107. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development.
    Cell. 1994 Mar 25;76(6):989-99 PMID: 8137432
  108. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.
    J Neurosci. 1995 Dec;15(12):7810-20 PMID: 8613721
  109. Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture.
    Mol Cell Neurosci. 2008 Jun;38(2):245-58 PMID: 18450476
  110. Brain-derived neurotrophic factor.
    Growth Factors. 2004 Sep;22(3):123-31 PMID: 15518235
  111. Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease.
    Parkinsonism Relat Disord. 2004 Jun;10(4):213-9 PMID: 15120095
  112. Stage-dependent BDNF serum concentrations in Alzheimer's disease.
    J Neural Transm (Vienna). 2006 Sep;113(9):1217-24 PMID: 16362629
  113. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease.
    Neuron. 1991 Nov;7(5):695-702 PMID: 1742020
  114. Role of brain-derived neurotrophic factor in Huntington's disease.
    Prog Neurobiol. 2007 Apr;81(5-6):294-330 PMID: 17379385
  115. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms.
    Ann Neurol. 2002 Jan;51(1):133-6 PMID: 11782995
  116. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease.
    Brain Pathol. 2008 Apr;18(2):225-38 PMID: 18093249
  117. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease.
    Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258(2):124-8 PMID: 17990049
  118. Lack of association between the brain-derived neurotrophin factor (C-270T) polymorphism and late-onset Alzheimer's disease (LOAD) in Brazilian patients.
    J Mol Neurosci. 2004;22(3):257-60 PMID: 14997020
Article Info
Journal
Nature reviews. Neurology
Abbr.
Nat Rev Neurol
ISSN
1759-4766
DOI
10.1038/nrneurol.2009.54
Published
2009-06-00
Pages
311-22
Language
English
Region
England
NLM ID
101500072
Subset
IM
Grants
Telethon · GGP06250 · Italy
External Links
PubMed source DOI: 10.1038/nrneurol.2009.54 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2